

1 **A reporter virus particle seroneutralization assay for tick-borne encephalitis virus**
2 **overcomes ELISA limitations**

3 Rahel Ackermann-Gäumann^{1,2}, Alexis Dentand³, Reto Lienhard^{1,2}, Mohsan Saeed^{4,5},
4 Margaret R. MacDonald⁶, Alix T Coste^{1,3}, Valeria Cagno^{1,3*}

5

6 ¹Swiss National Reference Centre for Tick-Transmitted Diseases, Switzerland

7 ²ADMED Microbiologie, La Chaux-de-Fonds 2300, Switzerland

8 ³Lausanne University Hospital, University of Lausanne, Switzerland

9 ⁴Department of Biochemistry & Cell Biology, Boston University Chobanian and Avedisian
10 School of Medicine, Boston University, MA 02118

11 ⁵National Emerging Infectious Diseases Laboratories, Boston University, MA 02118

12 ⁶Laboratory of Virology and Infectious Disease, The Rockefeller University, New York NY
13 10065

14

15

16

17

18 * To whom correspondence should be addressed.

19 Valeria Cagno

20 Institute of Microbiology of Lausanne

21 Rue du Bugnon 48

22 1011 Lausanne

23 +41213142611

24 valeria.cagno@chuv.ch

25

26 **ABSTRACT**

27 **Background** Tick-borne encephalitis (TBE) virus is the most common tick-transmitted
28 Orthoflavivirus in Europe. Due to its non-specific symptoms, TBE is primarily diagnosed by
29 ELISA-based detection of specific antibodies in the patient serum. However, cross-reactivity
30 between orthoflaviviruses complicates the diagnosis. Specificity problems may be overcome
31 by serum neutralization assays (SNT), however clinically relevant orthoflaviviruses require
32 handling in biosafety level 3 (BSL-3) and they have highly divergent viral kinetics and cell
33 tropisms.

34 **Methods** We present a reporter viral particle (RVP) based SNT in which the infectivity is
35 measured by luminescence and that can be performed under BSL-2 conditions.

36 **Findings** The RVP-based SNT for TBEV exhibited a remarkable correlation with the
37 traditional virus-based SNT ($R^2=0.8614$, $p<0.0001$). Notably, the RVP-based assay
38 demonstrated a sensitivity of 91.7% (95% CI: 87.2-97.1%) and specificity of 100% (95% CI:
39 79.6-100%). We also tested the cross-reactivity of serum samples in RVP-based assays
40 against other orthoflaviviruses (yellow fever virus, dengue virus type 2, Zika virus, West Nile
41 virus and Japanese encephalitis virus). Interestingly, in 90% of cases where a serum sample
42 had tested TBEV-positive by ELISA but negative by RVP-based SNT, we identified
43 antibodies against other orthoflaviviruses.

44 **Interpretations** The RVP-based seroneutralization assay show clinical relevance and broad-
45 applicability.

46 **Funding** This study was supported by Bavarian Nordic grant to R.A. and V.C.

47

48

49

50 **Keywords:** seroneutralization, TBEV, reporter viral particle, serology

51 **RESEARCH IN CONTEXT**

52 **Evidence before this study**

53 ELISA tests for orthoflavivirus serology are the method of choice in all diagnostic
54 laboratories despite the cross-reactivity issues. Although seroneutralization testing (SNT)
55 provides more reliable results, it requires BSL-3 conditions and approximately a week to
56 obtain the results. However, developing tests with a broader applicability could overcome the
57 problem of cross-reactivity of antibodies against flaviviruses could be overcome leading to a
58 more accurate diagnosis and fewer non-useful results. Although alternative serological tests
59 for other orthoflaviviruses have been investigated they have limitations, including lack of
60 uniformity for different orthoflaviviruses, the need for a BSL-3 laboratory to perform them,
61 and results taking 4-5 days. The reporter viral particle system (RVP) we used in this study has
62 been reported for all orthoflaviviruses, except for YFV. However, its applicability has not
63 been tested in comparison to traditional methods with clinical samples.

64 **Added value of this study**

65 We tested the RVP system uniformly for different orthoflaviviruses and evaluated the
66 sensitivity and specificity of SNT based on RVP compared to virus-based and to ELISA.
67 Additionally, we found that false positives in ELISA in our clinical samples are frequently
68 related to YFV positive samples.

69 **Implications of all the available evidence**

70 This study demonstrates the reliability and broad applicability of implementing RVP-based
71 SNT in a clinical setting. This test can overcome the issues of false positive results from
72 ELISA tests. Additionally, our data suggest that it is important to consider YFV exposure or
73 vaccination anamnesis in patient's medical history. This is consistent with the phylogenetic
74 similarity between YFV and TBEV if compared to other flaviviruses.

75

76 INTRODUCTION

77 Tick-borne encephalitis (TBE) caused by the tick-borne encephalitis virus (TBEV;
78 Orthoflavivirus encephalitidis, genus Orthoflavivirus, family *Flaviviridae*), is a major public
79 health problem in large parts of Europe and Asia. In Europe, TBE is endemic in at least 27
80 countries. TBE is typically caused by an infection involving one of three TBEV subtypes,
81 namely the European, Siberian, and Far Eastern subtypes. In addition, two other subtypes, i.e.
82 the Baikalian and the Himalayan subtype have been described more recently (1). TBEV is
83 primarily transmitted to humans by the bite of an infected Ixodid tick, although transmission
84 via the consumption of unpasteurized milk products from infected goats, sheep, or cows, is
85 also possible (2).

86 Despite the availability of effective vaccines, disease incidence has significantly increased
87 during the past years (1). TBE may manifest as a disease of variable severity, ranging from
88 subclinical infections to severe courses with neurological involvement and potentially fatal
89 outcomes. Symptomatic disease is typically biphasic when caused by European subtype
90 viruses, including a viremic stage with flu-like symptoms starting about 8 days (range 4–28
91 days) after the tick bite, an asymptomatic interval of about one week (range 1–33 days), and a
92 second stage with neurological manifestations ranging from mild meningitis to severe
93 encephalitis with or without myelitis and spinal paralysis (1, 3, 4).

94 TBEV virions are spherical and contain a nucleocapsid surrounded by a lipid bilayer. The
95 nucleocapsid consists of single-stranded positive-sense genomic RNA and the capsid protein
96 (C). The surface of the lipid membrane incorporates an envelope (E) and a membrane (M)
97 glycoprotein (5). In addition to the three structural proteins (C, E, and precursor M [prM]), the
98 viral genome encodes for seven nonstructural proteins (NS1, NS2A, NS2B, NS3, NS4A,
99 NS4B, and NS5).

100 Since clinical symptoms of TBE are often unspecific and similar to other central nervous
101 system diseases, the diagnosis of TBE has to be established in the laboratory. The methods of
102 choice for the diagnosis of TBE are serological assays (6). However, interpretation of
103 serologic test results is hampered by the high cross reactivity of the antigenic structure among
104 orthoflaviviruses, especially in areas where other orthoflaviviruses co-circulate or where
105 vaccination against other orthoflaviviruses is regularly used (3). Examples of other medically
106 relevant orthoflaviviruses include yellow fever virus (YFV; Orthoflavivirus flavi), dengue
107 virus (DENV; Orthoflavivirus denguei), Zika virus (ZIKV; Orthoflavivirus zikaense), West

108 Nile virus (WNV; Orthoflavivirus nilense), and Japanese encephalitis virus (JEV;
109 Orthoflavivirus japonicum). In Europe, WNV is endemic (7), whereas YFV, JEV, DENV, and
110 ZIKV infections are mainly described in association with travels to endemic areas (7-10).
111 However locally acquired cases of DENV have been described in recent years in different
112 European countries, including France in 2022 (11) and in Italy in 2023 (12). Vaccines against
113 JEV and YFV are administered prior to travelling to endemic areas, and simultaneous
114 administration of multiple vaccines is not uncommon (13, 14).

115 The antibody response to TBE is primarily targeted against the E and NS1 proteins of TBEV;
116 most neutralizing antibodies recognize the viral E protein (1, 15). In order to differentiate
117 neutralizing antibodies from cross-reactive non-neutralizing antibodies, plaque reduction
118 neutralization, or microneutralization tests are typically used for medically relevant
119 orthoflaviviruses, including TBEV. However, these tests are labor-intensive, time consuming,
120 and involve the handling of infectious virus.

121 Reporter virus particles (RVPs) have been used in neutralization assays to measure antibodies
122 against several orthoflaviviruses including DENV, YFV, JEV, and WNV (16-25). In
123 particular, a system using RVPs encapsidating a sub-genomic replicon capable of expressing a
124 reporter gene following infection of target cells has been described. In this approach,
125 production of RVPs is accomplished by complementation of replicon RNA with
126 orthoflavivirus structural genes expressed in trans (26). Here, we present a comprehensive
127 assessment of the TBEV RVP seroneutralization test (SNT) using clinical samples in direct
128 comparison with ELISA and virus-based SNT. In addition, we simultaneously assessed the
129 neutralization capacity of sera against YFV, DENV-2, ZIKV, WNV, and JEV using RVP-
130 based SNT assays. Our results underscore the shortcomings of traditional ELISA testing,
131 which sometimes yielded positive results for sera incapable of neutralizing TBEV. In contrast,
132 RVP-based SNT proved to be a robust alternative, comparable to virus-based SNT, and it can
133 be performed under BSL2 conditions. Notably, this method offers a significant advantage of
134 delivering results within 48h. Furthermore, cross-testing of serum samples against other
135 orthoflaviviruses provides a valuable means to directly discern the specificity of antibodies
136 within a given serum sample. These results argue for clinical implementation of RVP-based
137 seroneutralization testing of TBEV and other orthoflaviviruses.

138 **METHODS**

139 **Cell lines**

140 293T, 293F, A549, Vero, BHK21 and HUH 7 cells were obtained from the laboratory of
141 Sylvia Rothenberger (University of Lausanne, Lausanne) and Caroline Tapparel (University
142 of Geneva, Geneva) and cryopreserved at -196°C in liquid nitrogen. Individual aliquots were
143 thawed and serially passaged for a maximum of 15 passages. All cell lines were maintained in
144 DMEM (1X) + GlutaMAX™ + 4.5 g/L D-Glucose + 110 mg/L Sodium Pyruvate (Gibco,
145 ThermoFisher Scientific) supplemented with 10% of fetal bovine serum (FBS, Pan Biotech)
146 and penicillin/streptomycin 100 UI/ml (Gibco, ThermoFisher Scientific), in 75 m² culture
147 flasks (Sigma Aldrich) at 37°C in an incubator with 5% CO₂. Cell suspensions were prepared
148 by removing the cell culture medium from confluent flasks and detaching the cells with
149 0.05% Trypsin EDTA (Gibco, ThermoFisher Scientific). Cells were counted using trypan
150 blue staining (Sigma Aldrich) and a Neubauer counting chamber.

151

152 **Viruses**

153 TBEV strain Neudoerfl, strain Hypr, and YFV 17D, were kindly provided by Olivier Engler,
154 Spiez Laboratory, Switzerland. TBEV was grown on A549 cells, YFV on Vero cells. Viruses
155 were tittered by plaque assay on the cell line used for viral production, by infecting cells
156 preplated in 24 well plates at a density of 90,000 cells/well, with serial dilutions of viruses for
157 1h at 37°C, followed by removal of the inoculum and addition of 500 µl of DMEM
158 supplemented with methylcellulose 0.5%. The cells were fixed with formaldehyde 4% (Sigma
159 Aldrich) at 72hpi and stained with crystal violet (Sigma Aldrich). Viral stocks were stored at -
160 80°C.

161

162 **Plasmids**

163 The plasmids containing the CprME sequence of TBEV Neudoerfl (27), ZIKV H/PF/2013
164 (28), DENV-2 (29) were kindly provided by the Rockefeller University. The DENV2, WNV
165 CprME and the pWNVII-Rep-Ren-IB replicon encoding the Renilla luciferase gene were
166 generously given by Theodore C. Pierson from the National Institute of Health (NIH, USA)
167 (26). The CprME plasmid of JEV (17) was kindly provided by Steve Whitehead, NIH, USA.
168 Plasmids were propagated using MAX Efficiency™ Stbl2™ Competent Cells (ThermoFisher

169 Scientific) according to manufacturer instructions. Extraction and purification of plasmids
170 from transformed bacteria was performed using the PureLink™ HiPure Plasmid Midiprep Kit
171 (ThermoFisher Scientific) and following manufacturer's instructions.

172 The YFV (strain Asibi) CprME expression construct was generated as follows: The CMV
173 promoter region from pZIKV/HPF/CprME (plasmid described in (30), and obtained from Ted
174 Pierson, NIH) was amplified by PCR using primers RU-O-24611 and RU-O-24677. The
175 region encoding Asibi CprME was amplified from the plasmid pACNR-2015FLYF-Asibi
176 (PMC7426275, and GenBank MT093734) using oligos RU-O-24676 and RU-O-24678. After
177 gel purification of the PCR products, they were joined by assembly PCR and amplified using
178 oligos RU-O-24611 and RU-O-24678. The resultant PCR product was gel purified, digested
179 with SnaBI and SacII, and ligated overnight at 16°C using Toyobo Ligation High V2 ligase
180 into similarly digested and alkaline phosphatase treated pZIKV/HPF/CprME to generate
181 pYFV/Asibi/CprME. The ligation reaction was transformed into MC1061 E. coli cells, and
182 colonies selected on LB/carbenicillin plates for 20 h at 30°C. The sequence of the construct
183 was verified by Sanger sequencing using oligos RU-O-19736, RU-O-18162, RU-O-23860,
184 RU-O-24105, and RU-O-22695.

Oligo	Sequence (5' – 3')
RU-O-24611	CTTGACCGACAATTGCATGAAG
RU-O-24677	CTGAGCTTTACGACCAGACATAGCCTGCTTTTTTGTACAAAC
RU-O-24676	GTTTGTACAAAAAAGCAGGCTATGTCTGGTCGTAAAGCTCAG
RU-O-24678	TTCGAACCGCGGCTGGGTCTATTACGCCCAACTCCTAGAGACAAAAAC
RU-O-19736	CCTATTGACGTCAATGACGG
RU-O-18162	GACGTTGGCTGCGAGCCCTG
RU-O-23860	TTGGCTGTTCTAAGGAAAGTTAAGA
RU-O-24105	CTGACCATTGCCTACCTT
RU-O-22695	AAATAGCCCCTGAAAGGCAGA

185 **Table 1. Oligos for YFV CprME cloning.**

186

187 **RVP production and titration**

188 Co-transfection of the sub-genomic replicon WNVII-Rep-Ren-IB with a plasmid encoding
189 orthoflavivirus structural genes allows its replication, expression of luciferase, and packaging
190 by the structural proteins provided in trans to generate RVPs. These RVPs, expressing the
191 structural proteins of a specific orthoflavivirus (TBEV, ZIKV, DENV, WNV, JEV), can be
192 used for a single round of infection. RVPs were produced in 293T cells, seeded the day before
193 the transfection at 1×10^6 cells/well in poly-D-lysine-coated (ThermoFisher Scientific) 6-well

194 plates. Three μg of CprME plasmid and $1\mu\text{g}$ of the sub-genomic replicon pWNVII-Rep-Ren-
195 IB were co-transfected using lipofectamine 3000 (ThermoFisher Scientific) following
196 manufacturer's protocol. Lipid-DNA complexes were removed after 4h incubation at 37°C
197 and replaced with cell culture medium. The culture medium containing RVPs was collected
198 after 72-120 hours of incubation at 30°C , filtered through $0.2\ \mu\text{m}$ filters (Sigma, Aldrich), and
199 stored at -80°C in single-use aliquots.

200 Titration of RVPs was done by infecting HuH-7 cells plated in 96 well plates at a density of
201 1×10^4 cells/well with serial dilutions of RVPs at 37°C and assessing the luminescence 48
202 hours post infection (hpi). Luminescence was revealed with the Renilla-Glo® Luciferase
203 Assay System (Promega) following manufacturer's protocol. The luciferase signal was
204 assessed with a luminometer (TriStar LB 941 by Berthold Technologies and the MikroWin
205 2000 software).

206

207 **Serum samples**

208 Fifty-three clinical serum samples were provided by the University Hospital of Lausanne,
209 Switzerland. They had been sent to the diagnostic labs for routine testing for TBEV IgG and
210 IgM antibodies. The sera were heat-inactivated at 56°C for 30 min and were stored at -80°C .
211 Additional sera (n=41) negative or positive for IgG and/or IgM antibodies for different
212 orthoflaviviruses were obtained from the diagnostic laboratory ADMED Microbiologie,
213 Switzerland, the University Hospital of Geneva, Switzerland, a ring trial organization
214 (INSTAND, Germany) and Seracare (LGC clinical diagnostic). These serum samples were
215 used for an initial evaluation of the RVP SNT assay.

216

217 **TBEV IgG and IgM ELISA**

218 TBEV-specific IgG and IgM antibodies were quantified using the VIROTECH TBE IgG/IgM
219 ELISA kit (Virotech Diagnostic's GmbH, Germany) according to the manufacturer's
220 instructions. OD measurements at 450/620 nm were done using the Biotek 800/TS plate
221 reader, the calculations of the Virotech Units (VU) were then done manually according to the
222 manufacturer's instructions. The cutoff for borderline results was fixed at >9 VU and the
223 cutoff for positive results at >11 VU.

224

225 **Selection of suitable cell lines**

226 With the goal of identifying a common cell line for both RVP- and virus-based TBEV SNT,
227 several cell lines were tested for their ability to support infection by RVP and infectious virus.
228 The RVP infection was assessed by infecting cells with equal amounts of RVPs and
229 evaluating the luciferase expression at 48 hpi. The authentic virus infection was assessed by
230 monitoring the cytopathic effect of TBEV using cell viability assays. For this, 293T and HuH-
231 7 cells were either mock-infected or infected with the wild type (WT) virus. 293T cells were
232 seeded at 2×10^4 cells/well while HuH-7 cells at 1×10^4 cells/well in 96 well plates. Cells
233 were infected with 100 plaque-forming units (PFU) of TBEV Hypr or Neudoerfl. At 72 hpi,
234 96 hpi and 120 hpi, the culture medium was discarded, and the cells were washed with
235 DMEM (1X) without serum. Then, 50 μ L of MTT (Sigma Aldrich) diluted at 1:10 in DMEM
236 (1X) without serum was applied in each well. Cells were incubated at 37°C for 2h. The
237 supernatant was then discarded and replaced with 100 μ L of dimethyl sulfoxide (DMSO;
238 Sigma Aldrich) per well to lyse the cells. Absorbance of cells was measured at 570 nm with a
239 spectrophotometer.

240

241 **RVP serum neutralization test**

242 In order to facilitate simultaneous evaluation of serum samples for their neutralizing capacity
243 against various orthoflaviviruses, we established an RVP SNT protocol that can be applied
244 uniformly to all RVPs used in this study (TBEV, YFV, ZIKV, DENV, WNV, JEV). The day
245 before the assay, HuH-7 cells were seeded in a 96-well plate at a density of 1×10^4 cells/well.
246 The RVPs were diluted in DMEM supplemented with 2.5% FBS to a concentration of 1×10^4
247 RLU/well. 60 μ L of RVPs and 60 μ L of serum samples serially diluted 4-fold in DMEM
248 supplemented with 2.5% FBS were mixed in a 96 well V bottom plate and incubated for 1h at
249 37°C. Thereafter, the medium was removed from the cells in the 96-well plates, and the RVP
250 / serum sample mixture was added to the cells. A line of untreated control (containing RVP
251 and medium) and a line of uninfected control (containing only cell medium) were included in
252 every plate. This plate was then incubated for 48h at 37°C. To determine the results of
253 neutralization assays, 70 μ L of supernatant was discarded from each well and replaced with
254 50 μ L of Renilla-Glo® Luciferase Assay System (Promega). The luciferase signal was
255 assessed with a luminometer (TriStar LB 941 by Berthold Technologies and the MikroWin
256 2000 software). The concentration at which 99% of cell infection by the RVPs was inhibited

257 (IC₉₉) was determined with nonlinear regression with GraphPad by calculating the
258 percentages of infection at different dilutions compared to the infected untreated (i.e., no
259 serum sample added) control.

260

261 **Wild type virus serum neutralization test**

262 As a reference method for TBEV, we used a standard WT virus serum neutralization test
263 (virus-based SNT) to determine the neutralizing activity of serum samples. Similarly, results
264 obtained using the YFV RVP SNT were compared to those obtained using a YFV WT SNT.
265 All work with infectious viruses was performed in a BSL-3 laboratory. 96-well plates were
266 seeded with 1×10^4 HuH-7 cells/well the day before infection. 60 μ L of serum samples
267 serially diluted 4-fold were mixed with 60 μ L of WT virus suspension, corresponding to 100
268 PFU/well. After an incubation period of 1h at 37°C, the serum sample / virus mixture was
269 added to the cells in the 96-well plates, from which the medium had been removed. As for the
270 RVP neutralization assay, a line of untreated control (containing WT virus and medium) and a
271 line of uninfected control (containing only cell medium) were included in every plate. The
272 plate was incubated at 37° for 4 (TBEV Hypr, YFV) to 5 days (TBEV Neudoerfl). Cytopathic
273 effect was assessed by coloration of cells with crystal violet and optical microscopy. The IC₉₉
274 was determined based on the last dilution in which the sera showed complete protection from
275 cytopathic effect. The cutoff for a positive WT SNT result was set at >1:8.

276

277 **RVP SNT assay characteristics and cutoff definition**

278 The sensitivity and specificity of the TBEV RVP SNT were defined based on receiver
279 operating curve (ROC) analysis, for which we used the TBEV WT SNT results as a reference
280 standard. The cutoff for qualitative test evaluation (positive/negative) was defined based on
281 the maximal Youden's index (31). This cutoff value was implemented consistently across all
282 RVP SNTs.

283

284 **Correlation analysis**

285 We utilized a linear regression model to assess the correlation between the quantitative RVP
286 SNT and WT SNT results, as well as between the RVP SNT and the ELISA as well as the

287 WT SNT and the ELISA results. Graphs were constructed by reporting the log of the 1/IC99
288 of each serum for the RVP SNT, the WT SNT, or the IgG or IgM ELISA. All analyses were
289 performed using GraphPad Prism 9, a p value < 0.05 was considered as significant.

290

291 **Ethics approval**

292 Ethical authorization to re-use samples collected by the serology of CHUV has been granted
293 by CER-VD, project n°2023-01971.

294

295 **Data sharing**

296 Raw data of SNT are available upon reasonable requests to valeria.cagno@chuv.ch

297

298 **Role of the funding source**

299 The project was financed by a research grant from Bavarian Nordic, but the authors were
300 completely independent from the funding source regarding the study plan, analysis, writing
301 and submission. The salary of V.C is supported by the Swiss National Science
302 Foundation [PZ00P3_193,289]

303 **RESULTS**

304 **Optimization of SNT conditions**

305 With the goal to identify a common cell line for both RVP-based and virus-based SNT for
306 TBEV, three cell lines were tested for their ability to express the reporter gene following RVP
307 infection (Supplementary Figure 1A) and their potential to show a cytopathic effect upon WT
308 virus infection (Supplementary Figure 1B-C). TBEV stocks were produced in A549 cells.
309 However, these cells yielded poor luminescence signal following RVP infection compared to
310 other cell lines, indicating limited expression of replicon in these cells (Supplementary Figure
311 1A). Among the permissive cell lines, HuH-7 showed the best profile in both assays and was
312 therefore used in all subsequent experiments. These cells were also susceptible to RVPs
313 derived from WNV, JEV, YFV, DENV, and ZIKV (Supplementary Figure 1D).

314 Next, we evaluated the performance of RVP-based SNT assays using three to seven serum
315 samples for each of the TBEV, WNV, JEV, YFV, DENV, and ZIKV and two samples
316 negative for antibodies against the respective orthoflaviviruses included in this study (TBEV,
317 WNV, JEV, YFV, DENV, and ZIKV). For all positive samples, we were able to calculate the
318 IC₉₉ values using the respective RVP SNT assay, whereas none of the negative samples
319 exhibited neutralizing activity against their respective RVPs (Supplementary Figure 2).

320

321 **RVP SNT assay characteristics and cutoff definition**

322 The cutoff for qualitative test evaluation (negative/positive) of the TBEV RVP-based SNT
323 was defined by ROC analysis using TBEV virus-based SNT results as a reference. Youden's
324 index was maximal at a value of 1:40, with a test sensitivity of 91.7% (95% CI: 87.2-97.1%)
325 and a test specificity of 100% (95% CI: 79.6-100%) (Supplementary Figure 3). The cutoff
326 value of $\geq 1:40$, defined using this approach, was implemented consistently across all RVP
327 SNTs.

328

329 **RVP-based SNT and virus-based SNT results for TBEV**

330 A total of 53 serum samples for which TBEV-specific IgG and IgM titers had been assessed
331 by ELISA-based routine testing (Virotech TBE IgG/IgM ELISA kit) were analyzed using
332 RVP-based and virus-based (strain Neudoerfl) SNT assays. The results are shown in Table 2.

333 94.3% of samples (50/53) yielded concordant results with both RVP-based and virus-based
 334 SNT assays; the remaining 3 samples with discordant results are probably false-negative in
 335 the RVP-based SNT as compared to TBEV WT SNT. The results of the RVP-based assay
 336 differed from those of ELISA for 12 samples (22.6%). Of these, two samples were positive by
 337 RVP-based assay but negative or borderline by ELISA; both samples were confirmed positive
 338 by the virus-based SNT assay. Ten samples tested negative in RVP-based assay but positive
 339 in TBEV IgG ELISA (7 negative, 1 borderline, and 2 positive for IgM), whereof 8 were
 340 confirmed negative by virus-based SNT.

sample	ELISA ¹				RVP SNT ²		WT SNT ³		discording qualitative results ⁴		
	IgG qn	IgG ql	IgM qn	IgM ql	Ig tot. qn	Ig tot. ql	Ig tot. qn	Ig tot. ql	RVP SNT / WT SNT	RVP SNT / ELISA	WT SNT / ELISA
CH01	<9	n	<9	n	<1:8	n	<1:8	n			
CH02	<9	n	<9	n	<1:8	n	<1:8	n			
CH03	<9	n	<9	n	<1:8	n	<1:8	n			
CH04	<9	n	<9	n	<1:8	n	<1:8	n			
CH05	<9	n	<9	n	<1:8	n	<1:8	n			
CH06	<9	n	<9	n	<1:8	n	<1:8	n			
CH07	<9	n	<9	n	<1:8	n	<1:8	n			
CH08	<9	n	<9	n	<1:8	n	<1:8	n			
CH09	<9	n	<9	n	1:10	n	1:32	p	x		x
CH10	<9	n	<9	n	1:96	p	1:32	p		x	x
CH11	<9	n	<9	n	1:45	p	1:32	p		x	x
CH12	<9	n	14	p	1:49	p	1:128	p			
CH13	10	?	<9	n	1:39	n	1:8	n			
CH14	17	p	<9	n	<1:8	n	<1:8	n		x	x
CH15	21	p	<9	n	1:12	n	1:8	n		x	x
CH16	32	p	<9	n	<1:8	n	1:8	n		x	x
CH17	35	p	<9	n	<1:8	n	<1:8	n		x	x
CH18	24	p	<9	n	1:17	n	1:8	n		x	x
CH19	51	p	<9	n	<1:8	n	1:8	n		x	x
CH20	40	p	<9	n	<1:8	n	<1:8	n		x	x
CH21	24	p	<9	n	1:398	p	1:80	p			
CH22	32	p	<9	n	1:57	p	1:128	p			
CH23	60	p	<9	n	1:336	p	1:104	p			
CH24	34	p	<9	n	1:105	p	1:32	p			
CH25	60	p	<9	n	1:559	p	1:320	p			
CH26	45	p	<9	n	1:588	p	1:2720	p			
CH27	26	p	<9	n	1:533	p	1:200	p			
CH28	38	p	<9	n	1:55	p	1:80	p			

CH29	37	p	<9	n	1:64	p	1:320	p			
CH30	44	p	<9	n	1:83	p	1:32	p			
CH31	23	p	<9	n	1:125	p	1:32	p			
CH32	12	p	<9	n	1:85	p	1:32	p			
CH33	12	p	<9	n	1:54	p	1:32	p			
CH34	19	p	<9	n	1:336	p	1:128	p			
CH35	29	p	<9	n	1:47	p	1:128	p			
CH36	41	p	<9	n	1:74	p	1:128	p			
CH37	25	p	10	?	<1:8	n	1:80	p	x	x	
CH38	54	p	10	?	1:3145	p	1:3200	p			
CH39	14	p	14	p	1:16	n	1:8	n		x	x
CH40	41	p	21	p	1:8	n	1:32	p	x	x	
CH41	32	p	62	p	1:8183	p	1:3200	p			
CH42	17	p	13	p	1:215	p	1:200	p			
CH43	38	p	100	p	1:3921	p	1:2600	p			
CH44	17	p	45	p	1:1971	p	1:1280	p			
CH45	24	p	51	p	1:1641	p	1:2048	p			
CH46	34	p	21	p	1:40	p	1:512	p			
CH47	49	p	22	p	1:364	p	1:512	p			
CH48	30	p	65	p	1:2002	p	1:3584	p			
CH49	36	p	67	p	1:1579	p	1:512	p			
CH50	34	p	45	p	1:833	p	1:896	p			
CH51	47	p	50	p	1:143	p	1:896	p			
CH52	15	p	50	p	1:7032	p	1:12800	p			
CH53	38	p	31	p	1:291	p	1:128	p			


341

342 **Table 2. Anti-TBEV antibody test results of clinical samples.** ¹ *Virotech TBE IgG/IgM ELISA;*
343 *results are given in Virotech Units / ml; cutoffs for negative and positive results were set at ≤ 9 and*
344 *≥ 11 VU/ml, respectively. Values not divisible by 4 are obtained by the mean of two independent SNT; ²*
345 *TBEV reporter virus particle seroneutralization test; results are given as IC99; the cutoff for a*
346 *positive result was set at $\geq 1:40$; ³ TBEV wild type seroneutralization test; results are given as IC99;*
347 *the cutoff for a positive result was set at $> 1:8$; ⁴ discordance of qualitative results between different*
348 *tests are indicated with x. For this comparison, ELISA was regarded as positive if either IgG or IgM*
349 *or both tested positive; borderline ELISA results were regarded as negative.*

350

351 Linear regression analysis was used to assess the agreement between quantitative test results
352 obtained from RVP-based versus virus-based (strain Neudoerfl) SNT, as well as between
353 SNTs and ELISA (Figure 1). All correlations were significant ($p < 0.001$, T test for linear
354 regression). A high correlation coefficient (R^2 0.86) was obtained for RVP-based SNT versus

355 virus-based SNT (Figure 1A), RVP-based SNT versus IgM ELISA (R^2 0.89), and virus-based
356 SNT versus IgM ELISA (R^2 0.91) (Figure 1D, 1E).



357

358 **Figure 1. Linear regression analysis comparing results obtained using the TBEV RVP SNT, the**
359 **TBEV WT SNT, and TBEV IgG and IgM ELISA. SNT results are expressed as log 1/IC99, ELISA**
360 **results as log VU/ml. A) correlation between the TBEV RVP SNT and the TBEV WT SNT (strain**
361 **Neudoerfl). B) correlation between the TBEV RVP SNT and TBEV IgG ELISA results. C) correlation**
362 **between the TBEV WT SNT and TBEV IgG ELISA results. D) correlation between the TBEV RVP SNT**
363 **and TBEV IgM ELISA results. E) correlation between TBEV WT SNT and TBEV IgM ELISA results.**
364 *Linear regression was calculated with GraphPad Prism, correlation coefficient and p values (T test*

365 *for linear regression) are indicated in each panel. Dotted lines represent the cutoff of the respective*
366 *tests.*

367

368 **Impact of virus strain on virus-based SNT results**

369 For a subset of samples, we evaluated the concordance between RVP-based and virus-based
370 SNT results when using a different virus strain, Hypr, in the virus-based SNT. Qualitatively,
371 the virus based SNT results were identical in 17 out of 18 samples (94.4%) when using the
372 strains Neudoerfl and Hypr, while quantitative results showed some variation (Supplementary
373 Table 1). The linear regression comparing RVP (strain Neudoerfl) and virus-based (strain
374 Hypr) SNT results R^2 of 0.55, as compared to the R^2 value of 0.86 when comparing RVP-
375 based and virus-based (strain Neudoerfl) SNT, respectively (Supplementary Figure 4).

376

377 **Evaluation of selected sera for crossreactivity**

378 The results of the RVP-based assay differed from those of ELISA for 12 samples (22.6%).
379 These samples, one borderline in ELISA and negative in the RVP-based assay, and 7
380 additional, randomly selected samples were tested for their neutralizing potential against
381 RVPs of 5 different orthoflaviviruses (ZIKV, YFV, DENV, WNV, JEV). The results are
382 shown in Table 3. Nine of the 10 serum samples (90%) that were TBEV-positive by ELISA
383 but negative by RVP-based SNT tested positive for neutralizing antibodies against other
384 orthoflaviviruses. Moreover, we found that seven of the 15 ELISA-positive samples (46.7%)
385 contained neutralizing antibodies against multiple orthoflaviviruses.

sample	ELISA ¹				TBEV RVP SNT ²		ZIKV RVP SNT ²		YFV RVP SNT ²		DENV RVP SNT ²		WNV RVP SNT ²		JEV RVP SNT ²		Clinical information
	IgG qn	IgG ql	IgM qn	IgM ql	Ig tot. qn	Ig tot. ql	Ig tot. qn	Ig tot. ql	Ig tot. qn	Ig tot. ql	Ig tot. qn	Ig tot. ql	Ig tot. qn	Ig tot. ql	Ig tot. qn	Ig tot. ql	
CH41	32	p	62	p	1:8183	p	< 1:8	n	1:13	n	< 1:8	n	< 1:8	n	< 1:8	n	Diagnosed TBE case
CH43	38	p	100	p	1:3921	p	< 1:8	n	1:134	p	1:47	p	< 1:8	n	< 1:8	n	Diagnosed TBE case
CH21	24	p	<9	n	1:398	p	< 1:8	n	1:659	p	< 1:8	n	1:48	p	1:77	p	Vaccinated against TBEV, JEV, YFV
CH22	32	p	<9	n	1:57	p	< 1:8	n	1:185	p	< 1:8	n	1:20	n	1:649	p	Vaccinated against TBEV, JEV, YFV
CH23	60	p	<9	n	1:336	p	< 1:8	n	1:1132	p	< 1:8	n	< 1:8	n	< 1:8	n	Vaccinated against TBEV, YFV
CH39	14	p	14	p	1:16	n	< 1:8	n	1:90	p	< 1:8	n	1:36	n	< 1:8	n	Travel in Mexico, South Africa, Thailand, Peru
CH37	25	p	10	?	< 1:8	n	< 1:8	n	1:112	p	< 1:8	n	1:145	p	1:29	n	Neurological symptoms
CH40	41	p	21	p	1:8	n	< 1:8	n	1:1557	p	1:12	n	< 1:8	n	< 1:8	n	No data
CH14	17	p	<9	n	< 1:8	n	< 1:8	n	1:426	p	n.a.		n.a.		n.a.		Origin Vietnam
CH15	21	p	<9	n	1:12	n	< 1:8	n	1:1786	p	< 1:8	n	< 1:8	n	< 1:8	n	Travel in Brazil, Thailand, Mexico
CH16	32	p	<9	n	< 1:8	n	< 1:8	n	1:87	p	1:17	n	< 1:8	n	< 1:8	n	Meningo-encephalitis unknown etiology
CH18	24	p	<9	n	1:17	n	< 1:8	n	< 1:8	n	< 1:8	n	1:40	p	< 1:8	n	Neurological symptoms associated to glioblastoma
CH20	40	p	<9	n	< 1:8	n	< 1:8	n	1:54	p	1:102	p	< 1:8	n	1:20	n	Origin Indonesia
CH17	35	p	<9	n	< 1:8	n	< 1:8	n	1:1588	p	1:62	p	1:97	p	< 1:8	n	Diagnosed WNV infection. Tested positive for IgG for YFV, DENV and WNV. Tested positive for IgM for WNV
CH19	51	p	<9	n	< 1:8	n	1:8	n	< 1:8	n	< 1:8	n	< 1:8	n	< 1:8	n	Meningo-Encephalitis of unknown etiology
CH13	10	?	<9	n	1:39	n	< 1:8	n	1:22	n	< 1:8	n	< 1:8	n	1:11	n	Vaccinated with two doses of TBEV vaccine
CH10	<9	n	<9	n	1:96	p	< 1:8	n	< 1:8	n	< 1:8	n	< 1:8	n	< 1:8	n	No data

CH11	<9	n	<9	n	1:45	p	< 1:8	n	1:377	p	< 1:8	n	1:11	n	1:36	n	Vaccinated with one dose of TBEV - No vaccination for Yellow fever
CH06	<9	n	<9	n	< 1:8	n	< 1:8	n	< 1:8	n	< 1:8	n	< 1:8	n	< 1:8	n	No data
CH09	<9	n	<9	n	1:10	n	< 1:8	n	< 1:8	n	< 1:8	n	< 1:8	n	< 1:8	n	Vaccinated with two doses of TBEV vaccine – immunosuppressed patient

386 **Table 3. RVP SNT results against multiple orthoflaviviruses.** ¹ *Virotech TBE IgG/IgM ELISA; results are given in Virotech Units / ml; cutoffs for negative*
 387 *and positive results were set at ≤ 9 and ≥ 11 VU/ml, respectively;* ² *reporter virus particle seroneutralization test; results are given as IC99; the cutoff for a*
 388 *positive result was set at $\geq 1:40$. n.a. not assessed*

390 Clinical information was available for 17/20 samples. Thereof, 12 were in accordance with
391 (samples CH41, CH22, CH23, CH15, CH20, CH17) or partially matched the SNT results
392 (samples CH43, CH21, CH37, CH39, CH15, CH20, CH11), whereas 5 did not provide
393 sufficient evidence to explain the results obtained (samples CH14, CH19, CH09, CH18,
394 CH16).

395 Twelve of the 15 samples (80%) that were positive by TBEV IgG ELISA showed a
396 neutralizing activity against YFV. This percentage, although partly supported by the clinical
397 data, is surprisingly high when compared to the assumed seroprevalence of YFV in the
398 population. Nonetheless, the presence of YFV antibodies in these samples was confirmed by
399 both RVP-based and virus-based SNT (Supplementary Table 2). with full qualitative
400 concordance between the two methods.

401 **DISCUSSION**

402 Despite the availability of effective vaccines, TBEV continues to pose a considerable threat to
403 public health due to its expanding geographical distribution and the increasing number of
404 reported cases (1). Serological diagnosis plays a crucial role in the management and
405 surveillance of TBEV infections. However, it is fraught with challenges, primarily stemming
406 from the cross-reactivity among orthoflaviviruses. This cross-reactivity can result in false-
407 positive results and misdiagnosis, especially in regions where multiple orthoflaviviruses co-
408 circulate, for persons having traveled to areas endemic for other orthoflaviviruses, or for
409 persons recently vaccinated against other orthoflaviviruses (3). While most laboratories use
410 ELISA for routine serological diagnosis, a reliable differentiation of virus-neutralizing from
411 cross-reactive virus-binding but non-neutralizing antibodies is only possible using serum
412 neutralization tests. Here, we describe the evaluation of an RVP-based test system, allowing
413 for the simultaneous detection of antibodies directed against multiple orthoflaviviruses. The
414 RVP-based SNT can serve as a rapid (within 48 hours) substitute for the virus-based SNT,
415 requiring only BSL-2 facilities and demonstrating a reliable performance. The concurrent
416 identification of antibodies against other orthoflaviviruses holds significant importance.

417 RVP-based SNTs for different orthoflaviviruses have been established using different cell
418 lines, including BHK-J cells (24), BHK-21 cells (26), Vero cells (25), and HUH-7.5 cells
419 (27). In our experiments, we found that HUH7 cells were well suited for the effective
420 execution of TBEV, YFV, DENV, ZIKV, WNV, and JEV RVP SNTs. The readout of our
421 assay using Renilla luciferase was performed 48hpi, which is in line with the readout of a test
422 using Gaussia luciferase (32), while others described readout times of 3 to 5-6 days using
423 NanoLuc or GFP, respectively(33, 34).

424 A major difficulty when establishing diagnostic tests is the definition of an appropriate cutoff,
425 which discriminates positive from negative results and requires a compromise between
426 sensitivity and specificity. We performed an ROC analysis and set the cutoff point for the
427 TBEV RVP-based SNT at the value resulting in the highest Youden's index, maximizing the
428 summation of sensitivity and specificity (31). One of the possible limitations of our study is
429 that cutoff values were not defined for each orthoflavivirus RVP SNTs individually, but rather
430 by applying the cutoff defined for the TBEV RVP SNT to all other test systems While this
431 offers the opportunity of harmonizing the readout of all tests, sensitivity and / or specificity of
432 RVP-based SNTs other than TBEV might not be optimal. Due to the small sample size, an

433 individual cutoff definition based on ROC analysis for each individual RVP SNT was not
434 possible in this study.

435 When compared to the virus-based SNT (strain Neudoerfl), the RVP-based SNT showed a
436 sensitivity of 91.7% and a specificity of 100% for TBEV. Assay specificity is of high
437 importance for a diagnostic assay that may be used as a confirmatory test. An assay sensitivity
438 of 91.7% is acceptable, though not optimal. On the other hand, we did also observe positive
439 results by RVP-based SNT for samples testing negative in ELISA (samples CH10, CH11,
440 Table 2), which were confirmed positive by the virus-based SNT. Thus, while ELISA tests for
441 the detection of anti-TBEV IgG antibodies generally show a high sensitivity, reaching up to
442 99% (35), it is important to acknowledge the potential for false-negative outcomes in these
443 assays. Given the quick availability of results with the RVP-based SNT, opting for this test
444 may offer advantages.

445 Discording results were obtained for 22.6% of samples (12/53) when comparing the RVP-
446 based SNT to ELISA. Thereof, 10 were false-positive in ELISA. The pronounced cross-
447 reactivity of antibodies against different orthoflaviviruses in ELISA test systems is well
448 known (3). In fact, we could demonstrate the presence of antibodies against other
449 orthoflaviviruses in 9/10 samples yielding false-positive results by ELISA (Table 3).
450 Neurological symptoms of TBE are similar to those of other viral infections of the brain,
451 including for instance WNV, which is endemic in Europe (7). Conducting a test that can both
452 rule out cross-reactivity and simultaneously evaluate specific seroneutralization for multiple
453 orthoflaviviruses is thus highly clinically significant. This capability is one of the significant
454 advantages provided by the here-described RVP-based SNTs.

455 Interestingly, the results of IgM ELISA showed a higher level of correlation with those from
456 RVP-based SNT (R^2 0.89, Figure 1D) and virus-based SNT (R^2 0.91, Figure 1E) compared to
457 those from IgG ELISA (R^2 0.27 and 0.37, respectively, Figure 1B and 1C). This discrepancy
458 likely arises from the fact that a substantial number of samples that test positive solely for IgG
459 are from individuals who have been vaccinated against different (crossreactive)
460 orthoflaviviruses or have recovered from an earlier infection, whereas those that also test
461 positive for IgM are typically associated with clinical TBE cases. It is also in line with the
462 observation that tests for anti-TBEV IgM are usually more specific than IgG tests with regard
463 to cross-reactivity with other orthoflaviviruses (36, 37).

464 While there was a strong correlation between RVP-based and virus-based SNT assays when
465 the strain Neudoerfl was used in both assays (R^2 0.86, Figure 1A), TBEV RVP SNT results
466 correlated less well to TBEV WT SNT results using the strain Hypr (R^2 0.55, Supplementary
467 Figure 4), as expected since the TBEV RVP utilized in this study is derived from the genetic
468 sequence of the Neudoerfl strain of TBEV. The results are in line with literature, where it has
469 been shown that antibodies generated upon vaccination with specific strains do not equally
470 efficiently neutralize different wild type virus strains (38, 39).

471 Among the subset of samples tested for their neutralizing capacity against multiple
472 orthoflaviviruses, we found a high proportion of samples (8/20) positive for antibodies against
473 more than one virus (Table 3). Thus, multiple vaccinations or exposures were common in this
474 set of samples, as verified in some cases by concordance between clinical information and
475 SNT results. However, for some sera the clinical information did not provide sufficient
476 evidence to explain the SNT results or only partially matched the SNT results, possibly linked
477 to an incomplete dataset or anamnesis may not have included questions about different
478 orthoflavivirus vaccinations. Our findings underscore the importance of simultaneous testing
479 against a large panel of orthoflaviviruses. Only by doing so can we unveil the complete range
480 of neutralizing antibodies present in a sample.

481 Remarkably, a significant number of samples yielded positive results for neutralizing
482 antibodies against YFV (Table 3). To address concerns about the specificity of the YFV RVP-
483 based SNT, all results were verified using the virus-based SNT (Supplementary Table 2). The
484 observed positivity rate is likely influenced by our choice to conduct RVP SNTs for multiple
485 orthoflaviviruses on selected samples. This selection primarily relied on discordant outcomes
486 between TBEV ELISA and TBEV RVP SNT results. Nevertheless, YFV vaccination is a non-
487 negligible cause of false-positive TBEV (IgG) ELISA results, given the (travel) vaccination
488 recommendations. However, it is important to consider that YFV vaccination can significantly
489 contribute to false-positive TBEV (IgG) ELISA results, especially in light of travel
490 vaccination guidelines (40) and the phylogenetic similarity of YFV to TBEV (12).

491 We found two samples positive in TBEV ELISA testing but negative in all orthoflavivirus
492 RVP-based SNTs (TBEV, ZIKV, YFV, DENV, WNV, JEV). While this might be due to
493 false-negative results in RVP-based SNTs, we must also keep in mind other less-well
494 characterized orthoflaviviruses which might be of medical importance but have not been
495 included in our study. These could be tick-borne (e.g., Powassan virus [*Orthoflavivirus*
496 *powassense*], Omsk hemorrhagic fever virus [*Orthoflavivirus omskense*] or mosquito borne

497 pathogens (e.g., Usutuivirus [*Orthoflavivirus usutuense*], Wesselsbron virus [*Orthoflavivirus*
498 *wesselsbronense*]) (41, 42).

499 Taken together, our results emphasize the importance of performing neutralization instead of
500 ELISA testing for diagnosing orthoflaviviral infections. While this has been labor-intensive
501 and requiring high biosafety level standards, the RVP-based neutralization approach for
502 multiple orthoflaviviruses we described provides a notable advantage, offering a more
503 accessible and cost-effective platform and thus enhancing the diagnostic capabilities of
504 healthcare institutions.

505

506 **ACKNOWLEDGEMENTS**

507 The authors would like to thank Emilie Ruegger and Alexandre Mamin for their support in
508 providing the sera, Adriana Renzoni for providing reference sera from the Swiss Center for
509 Emerging viruses and the members of the Swiss National Reference Center for Tick
510 Transmitted Diseases for fruitful discussions.

511 REFERENCES

- 512 1. Ruzek D, Avsic Zupanc T, Borde J, Chrdle A, Eyer L, Karganova G, et al. Tick-borne encephalitis
513 in Europe and Russia: Review of pathogenesis, clinical features, therapy, and vaccines. *Antiviral Res.*
514 2019;164:23-51.
- 515 2. Martello E, Gillingham EL, Phalkey R, Vardavas C, Nikitara K, Bakonyi T, et al. Systematic
516 review on the non-vectorial transmission of Tick-borne encephalitis virus (TBEv). *Ticks Tick Borne Dis.*
517 2022;13(6):102028.
- 518 3. Lindquist L. Tick-borne encephalitis. In: Tselis A, editor. *Handbook of Clinical NEurology*:
519 Elsevier; 2014. p. 531-59.
- 520 4. Lindquist L, Vapalahti O. Tick-borne encephalitis. *Lancet.* 2008;371(9627):1861-71.
- 521 5. Fuzik T, Formanova P, Ruzek D, Yoshii K, Niedrig M, Plevka P. Structure of tick-borne
522 encephalitis virus and its neutralization by a monoclonal antibody. *Nat Commun.* 2018;9(1):436.
- 523 6. Holzmann H. Diagnosis of tick-borne encephalitis. *Vaccine.* 2003;21 Suppl 1:S36-40.
- 524 7. Kaaijk P, Luytjes W. Are we prepared for emerging flaviviruses in Europe? Challenges for
525 vaccination. *Hum Vaccin Immunother.* 2018;14(2):337-44.
- 526 8. Overbosch FW, Schinkel J, Matser A, Koen G, Prange I, Prins M, et al. Dengue, chikungunya
527 and Zika virus infections among Dutch travellers to Suriname: a prospective study during the
528 introduction of chikungunya and Zika virus, 2014 to 2017. *Euro Surveill.* 2023;28(2).
- 529 9. Wiltz P. Identifying and Managing Vector-Borne Diseases in Migrants and Recent Travelers in
530 the Emergency Department. *Curr Emerg Hosp Med Rep.* 2023;11(2):58-65.
- 531 10. Amicizia D, Zangrillo F, Lai PL, Iovine M, Panatto D. Overview of Japanese encephalitis disease
532 and its prevention. Focus on IC51 vaccine (IXIARO((R))). *J Prev Med Hyg.* 2018;59(1):E99-E107.
- 533 11. Cochet A, Calba C, Jourdain F, Grard G, Durand GA, Guinard A, et al. Autochthonous dengue
534 in mainland France, 2022: geographical extension and incidence increase. *Euro Surveill.* 2022;27(44).
- 535 12. Del Manso M DME, Perego G, Petrone D, Mateo-Urdiales A, Caporali MG, Bella A, Venturi G,
536 Di Luca M, Giannitelli S, Ferraro F, Pezzotti P, Riccardo F. Arbovirosi in Italia - 2023
537 <https://www.epicentro.iss.it/arbovirosi/dashboard2023> [updated 11.09.2023. Available from:
538 <https://www.epicentro.iss.it/arbovirosi/dashboard>.
- 539 13. Jaeger VK, Tschudi N, Ruegg R, Hatz C, Buhler S. The elderly, the young and the pregnant
540 traveler -- A retrospective data analysis from a large Swiss Travel Center with a special focus on
541 malaria prophylaxis and yellow fever vaccination. *Travel Med Infect Dis.* 2015;13(6):475-84.
- 542 14. Sandberg JT, Lofling M, Varnaite R, Emgard J, Al-Tawil N, Lindquist L, et al. Safety and
543 immunogenicity following co-administration of Yellow fever vaccine with Tick-borne encephalitis or
544 Japanese encephalitis vaccines: Results from an open label, non-randomized clinical trial. *PLoS Negl*
545 *Trop Dis.* 2023;17(2):e0010616.
- 546 15. Chambers TJ, Diamond MS. Pathogenesis of flavivirus encephalitis. *Adv Virus Res.*
547 2003;60:273-342.
- 548 16. Gehrke R, Ecker M, Aberle SW, Allison SL, Heinz FX, Mandl CW. Incorporation of tick-borne
549 encephalitis virus replicons into virus-like particles by a packaging cell line. *J Virol.* 2003;77(16):8924-
550 33.
- 551 17. Gromowski GD, Firestone CY, Hanson CT, Whitehead SS. Japanese encephalitis virus vaccine
552 candidates generated by chimerization with dengue virus type 4. *Vaccine.* 2014;32(25):3010-8.
- 553 18. Garg H, Mehmetoglu-Gurbuz T, Joshi A. Virus Like Particles (VLP) as multivalent vaccine
554 candidate against Chikungunya, Japanese Encephalitis, Yellow Fever and Zika Virus. *Sci Rep.*
555 2020;10(1):4017.
- 556 19. Jones CT, Patkar CG, Kuhn RJ. Construction and applications of yellow fever virus replicons.
557 *Virology.* 2005;331(2):247-59.
- 558 20. Pierson TC, Diamond MS, Ahmed AA, Valentine LE, Davis CW, Samuel MA, et al. An infectious
559 West Nile virus that expresses a GFP reporter gene. *Virology.* 2005;334(1):28-40.

- 560 21. Mattia K, Puffer BA, Williams KL, Gonzalez R, Murray M, Sluzas E, et al. Dengue reporter virus
561 particles for measuring neutralizing antibodies against each of the four dengue serotypes. *PLoS One*.
562 2011;6(11):e27252.
- 563 22. Garg H, Sedano M, Plata G, Punke EB, Joshi A. Development of Virus-Like-Particle Vaccine and
564 Reporter Assay for Zika Virus. *J Virol*. 2017;91(20).
- 565 23. Agudelo M, Palus M, Keeffe JR, Bianchini F, Svoboda P, Salát J, et al. Broad and potent
566 neutralizing human antibodies to tick-borne flaviviruses protect mice from disease. *J Exp Med*.
567 2021;218(5).
- 568 24. Lücke AC, Vom Hemdt A, Wieseler J, Fischer C, Feldmann M, Rothenfusser S, et al. High-
569 Throughput Platform for Detection of Neutralizing Antibodies Using Flavivirus Reporter Replicon
570 Particles. *Viruses*. 2022;14(2).
- 571 25. Bohning K, Sonnberg S, Chen HL, Zahralban-Steele M, Powell T, Hather G, et al. A high
572 throughput reporter virus particle microneutralization assay for quantitation of Zika virus neutralizing
573 antibodies in multiple species. *PLoS One*. 2021;16(4):e0250516.
- 574 26. Pierson TC, Sanchez MD, Puffer BA, Ahmed AA, Geiss BJ, Valentine LE, et al. A rapid and
575 quantitative assay for measuring antibody-mediated neutralization of West Nile virus infection.
576 *Virology*. 2006;346(1):53-65.
- 577 27. Agudelo M, Palus M, Keeffe JR, Bianchini F, Svoboda P, Salát J, et al. Broad and potent
578 neutralizing human antibodies to tick-borne flaviviruses protect mice from disease. *J Exp Med*.
579 2021;218(5).
- 580 28. Dowd KA, DeMaso CR, Pelc RS, Speer SD, Smith ARY, Goo L, et al. Broadly Neutralizing Activity
581 of Zika Virus-Immune Sera Identifies a Single Viral Serotype. *Cell Rep*. 2016;16(6):1485-91.
- 582 29. Ansarah-Sobrinho C, Nelson S, Jost CA, Whitehead SS, Pierson TC. Temperature-dependent
583 production of pseudoinfectious dengue reporter virus particles by complementation. *Virology*.
584 2008;381(1):67-74.
- 585 30. Robbiani DF, Bozzacco L, Keeffe JR, Khouri R, Olsen PC, Gazumyan A, et al. Recurrent Potent
586 Human Neutralizing Antibodies to Zika Virus in Brazil and Mexico. *Cell*. 2017;169(4):597-609 e11.
- 587 31. Habibzadeh F, Habibzadeh P, Yadollahie M. On determining the most appropriate test cut-off
588 value: the case of tests with continuous results. *Biochem Med (Zagreb)*. 2016;26(3):297-307.
- 589 32. Lucke AC, Vom Hemdt A, Wieseler J, Fischer C, Feldmann M, Rothenfusser S, et al. High-
590 Throughput Platform for Detection of Neutralizing Antibodies Using Flavivirus Reporter Replicon
591 Particles. *Viruses*. 2022;14(2).
- 592 33. Li W, Ma L, Guo LP, Wang XL, Zhang JW, Bu ZG, et al. West Nile virus infectious replicon
593 particles generated using a packaging-restricted cell line is a safe reporter system. *Sci Rep*.
594 2017;7(1):3286.
- 595 34. Matsuda M, Yamanaka A, Yato K, Yoshii K, Watashi K, Aizaki H, et al. High-throughput
596 neutralization assay for multiple flaviviruses based on single-round infectious particles using dengue
597 virus type 1 reporter replicon. *Sci Rep*. 2018;8(1):16624.
- 598 35. Litzba N, Zelena H, Kreil TR, Niklasson B, Kuhlmann-Rabens I, Remoli ME, et al. Evaluation of
599 different serological diagnostic methods for tick-borne encephalitis virus: enzyme-linked
600 immunosorbent, immunofluorescence, and neutralization assay. *Vector Borne Zoonotic Dis*.
601 2014;14(2):149-59.
- 602 36. Reusken C, Boonstra M, Rugebregt S, Scherbeijn S, Chandler F, Avsic-Zupanc T, et al. An
603 evaluation of serological methods to diagnose tick-borne encephalitis from serum and cerebrospinal
604 fluid. *J Clin Virol*. 2019;120:78-83.
- 605 37. Dobler G. *Diagnosis. The TBE book*. 6th edition ed: Global Health Press; 2023.
- 606 38. Bestehorn-Willmann M, Giral P, Greiner F, Mackenstedt U, Dobler G, Lang D. Increased
607 Vaccination Diversity Leads to Higher and Less-Variable Neutralization of TBE Viruses of the European
608 Subtype. *Vaccines (Basel)*. 2023;11(6).
- 609 39. Geissreiter B, Kluger G, Eschermann K, Kiwull L, Staudt M, Dobler G, et al. High neutralizing
610 antibody mismatch as a possible reason for vaccine failure in two children with severe tick-borne
611 encephalitis. *Ticks Tick Borne Dis*. 2023;14(4):102158.

- 612 40. Control CfD. Yellow Fever Vaccine 2021 [Available from:
613 <https://www.cdc.gov/yellowfever/vaccine/index.html>.
614 41. Baryshnikova V, Turchenko Y, Tuchynskaya K, Belyaletdinova I, Butenko A, Dereventsova A, et
615 al. Recombinant TBEV Protein E of the Siberian Subtype Is a Candidate Antigen in the ELISA Test
616 System for Differential Diagnosis. *Diagnostics (Basel)*. 2023;13(20).
617 42. Pierson TC, Diamond MS. The continued threat of emerging flaviviruses. *Nat Microbiol*.
618 2020;5(6):796-812.
- 619